XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company has raised US$4.5 million in funding for its AI operating system
European operations' revenue grew 58.4% to Rs 599.7 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
